Two Sigma Advisers
RLAY icon

Two Sigma Advisers’s Relay Therapeutics RLAY Stock Holding History

Two Sigma Advisers’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,289,800
Closed -$10.9M – 1699
2025
Q4 		$10.9M Buy
1,289,800
+165,500
+15% +$1.18M 0.02% 513
2025
Q3 		$5.87M Sell
1,124,300
-15,500
-1% -$59.1K 0.01% 685
2025
Q2 		$3.94M Buy
1,139,800
+388,600
+52% +$1.16M 0.01% 827
2025
Q1 		$1.97M Buy
751,200
+112,300
+18% +$440K ﹤0.01% 1162
2024
Q4 		$2.63M Buy
638,900
+24,700
+4% +$134K 0.01% 1003
2024
Q3 		$4.35M Buy
614,200
+189,400
+45% +$1.41M 0.01% 755
2024
Q2 		$2.77M Buy
424,800
+30,500
+8% +$208K 0.01% 1019
2024
Q1 		$3.27M Buy
394,300
+64,700
+20% +$631K 0.01% 965
2023
Q4 		$3.63M Buy
329,600
+24,400
+8% +$206K 0.01% 964
2023
Q3 		$2.57M Buy
305,200
+290,800
+2,019% +$3.13M 0.01% 1063
2023
Q2 		$181K Buy
14,400
+2,600
+22% +$32.3K ﹤0.01% 2116
2023
Q1 		$194K Sell
11,800
-29,800
-72% -$534K ﹤0.01% 2276
2022
Q4 		$622K Buy
41,600
+22,100
+113% +$423K ﹤0.01% 1791
2022
Q3 		$436K Buy
+19,500
New +$428K ﹤0.01% 1897

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Two Sigma Advisers's RLAY Position: Q1 2026 in Review

Two Sigma Advisers sold out of Relay Therapeutics (RLAY) in Q1 2026, closing a stake of 1,289,800 shares — an estimated $10.9M sold.

Two Sigma Advisers first reported a position in RLAY in Q3 2022 and held it in 14 quarters. The position peaked at $10.9M in Q4 2025. 244 funds tracked by Wall St. Rank hold RLAY as of Q1 2026.

  • Two Sigma Advisers reported no remaining Relay Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Two Sigma Advisers sold 1,289,800 Relay Therapeutics shares in Q1 2026, an estimated $10.9M.
  • Two Sigma Advisers first reported a position in Relay Therapeutics in Q3 2022 and held it in 14 quarters.
  • Two Sigma Advisers's Relay Therapeutics position peaked at $10.9M in Q4 2025.
  • 244 funds tracked by Wall St. Rank held Relay Therapeutics as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.